Posted by Michael Wonder on 28 Apr 2023
FDA approves Otsuka and Lundbeck’s Abilify Asimtufii (aripiprazole), the first once every two months long-acting injectable for the treatment of schizophrenia or maintenance monotherapy treatment of bipolar I disorder in adults
27 April 2023 - Otsuka and Lundbeck announce the US FDA has approved the new drug application for Abilify Asimtufii (aripiprazole) extended-release injectable suspension for intramuscular use, a once every two months injection for the treatment of schizophrenia in adults or for maintenance monotherapy treatment of bipolar I disorder in adults.
Abilify Asimtufii offers two months of sustained therapeutic concentrations with one dose.
